In-Vivo Assessment of Silver Biomaterial Nano-Toxicity 32 Ppm

May 25, 2016 updated by: mark munger, University of Utah
The investigators propose to study oral commercial silver nanoparticle products on human enzyme activity.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
12

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Utah
      • Salt Lake City, Utah, United States, 84112-5820
        • University of Utah

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 18-80 years old without debilitating chronic disease or history of cardiovascular event.

Exclusion Criteria:

  • Women physically capable of becoming pregnant, who are not using 2 barrier methods of birth control;
  • Any female who is nursing;
  • History of heavy metal allergy;
  • History of asthma or Chronic Obstructive Pulmonary Disease;
  • History of renal impairment;
  • Symptoms of active upper respiratory disease at time of consent;
  • Smoking more than 5 cigarettes or equivalent and not able to stop for 48 hours;
  • Ability to discontinue chronic medications or nutraceuticals for 20 days or 5 half-lives of the agent, whichever is longer.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Non-Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: 32ppm Oral Silver
14 Days Active Silver Solution
Drug: 32ppm Silver Particle
Oral silver dose of 32ppm
Placebo Comparator: Sterile Water
No Silver Nanoparticles
Drug: Placebo
Sterile Water No Silver

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change Sodium Blood Levels
Time Frame: 14 Days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 Days
Change Potassium Blood Levels
Time Frame: 14 days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 days
Change in Chloride Blood Levels
Time Frame: 14 days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 days
Change in Carbon Dioxide Blood Levels
Time Frame: 14 days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 days
Change In Urea Nitrogen Blood Levels
Time Frame: 14 days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 days
Change In Creatinine Blood Levels
Time Frame: 14 Days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 Days
Change In Glucose Blood Levels
Time Frame: 14 Days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 Days
Change In Alkaline Phosphatase Blood Level
Time Frame: 14 Days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 Days
Change In Aspartate Aminotransferase Blood Level
Time Frame: 14 Days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 Days
Change In Alanine Aminotransferase Blood Level
Time Frame: 14 Days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 Days
Change in Total Protein Blood Levels
Time Frame: 14 Days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 Days
Change In Total Bilirubin Blood Levels
Time Frame: 14 Days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 Days
Change In Albumin Blood Levels
Time Frame: 14 Days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 Days
Change In Calcium Blood Level
Time Frame: 14 Days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 Days
Change In White Blood Count Blood Levels
Time Frame: 14 Days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 Days
Change In Red Blood Count Blood Levels
Time Frame: 14 Days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 Days
Change In Hemoglobin Blood Levels
Time Frame: 14 Days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 Days
Change In Hematocrit Blood Levels
Time Frame: 14 Days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 Days
Change In Mean Corpuscular Volume Blood Levels
Time Frame: 14 Days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 Days
Change In Mean Corpuscular Hemoglobin Concentration Blood Levels
Time Frame: 14 Days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 Days
Change In Platelet Blood Levels
Time Frame: 14 Days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 Days
Change In Granulocytes Blood Levels
Time Frame: 14 Days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 Days
Change In Lymphocytes Blood Levels
Time Frame: 14 Days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 Days
Change In Monocytes Blood Levels
Time Frame: 14 Days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 Days
Change In Basophils Blood Levels
Time Frame: 14 Days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 Days
Change In Eosinophils Blood Levels
Time Frame: 14 Days
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
14 Days
Cytochrome P450 Assay on Dextromethorphan in Participants
Time Frame: 14 Days
Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days). Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized. The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.
14 Days
Cytochrome P450 Assay on Losartan in Participants
Time Frame: 14 Days
Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days). Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized. The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.
14 Days
Cytochrome P450 Assay on Caffeine in Participants
Time Frame: 14 Days
Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days). Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized. The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.
14 Days
Cytochrome P450 Assay on Omeprazole in Participants
Time Frame: 14 Days
Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days). Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized. The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.
14 Days
Cytochrome P450 Assay on Midazolam in Participants
Time Frame: 14 Days
Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days). Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized. The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.
14 Days

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Cytochrome P450 Assay on Chlorozoxazone in Participants Dosed With Silver
Time Frame: 14 Days
Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days). Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized. The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.
14 Days
Total Change in Systolic Blood Pressure Silver Participants
Time Frame: Baseline and 14 Days
Assessment only completed on the 32ppm Oral Silver part of the trail
Baseline and 14 Days
Total Change in Diastolic Blood Pressure Silver Participants
Time Frame: Baseline and 14 Days
Assessment only completed on the 32ppm Oral Silver part of the trail
Baseline and 14 Days
Total Change in Heart Rate in Silver Participants
Time Frame: Baseline and 14 Days
Assessment only completed on the 32ppm Oral Silver part of the trail
Baseline and 14 Days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Utah

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Mark Munger, Pharm.D., University of Utah

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 1, 2011

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 1, 2011

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
November 1, 2011

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 19, 2011

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 28, 2011

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 29, 2011

Study Record Updates

Last Update Posted (Estimate)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 4, 2016

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 25, 2016

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 50310 (MSD Sharp&Dohme GmbH)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings